Suzetrigine VX-548 Physical Engineering and Cellular Interaction Analysis

Suzetrigine (VX-548) represents a landmark advancement in analgesic pharmacology — the first selective Nav1.8 sodiumchannel blocker to achieve regulatory approval. Approved by the U.S. Food and Drug Administration (FDA) in January 2025under the brand name Journavx, this molecule provides effective pain relief without engaging the μ-opioid receptor pathway,thereby circumventing the addiction, respiratory depression, and tolerance liabilities that have defined the opioid crisis. Thisresearch synthesizes the physical, engineering, and mathematical frameworks that govern Suzetrigine's behavior withinhuman cellular systems.